Nurix Stock Is Down 6% This Past Year, but One Biotech Fund Still Boosted Its Bet By $63 Million
2026-02-22 13:32:40 ET
On February 17, 2026, Redmile Group disclosed a buy of 4,415,514 Nurix Therapeutics (NASDAQ:NRIX) shares, an estimated $63.43 million trade based on quarterly average pricing.
According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group bought 4,415,514 additional shares of Nurix Therapeutics (NASDAQ:NRIX) . The estimated transaction value was $63.43 million, calculated using the mean unadjusted close for the fourth quarter of 2025. At quarter-end, the value of Redmile’s Nurix Therapeutics position increased by $119.55 million, a figure that incorporates both new share purchases and changes in the stock price.
Nurix Therapeutics, Inc. is a biotechnology company leveraging targeted protein modulation to address unmet needs in oncology and immune disorders. The company pursues a pipeline of innovative therapies and partners with major pharmaceutical firms to advance its clinical programs. Its strategic collaborations and proprietary platform position it to compete in the rapidly evolving biopharmaceutical landscape.
NASDAQ: NRIX
NRIX Trading
-4.2% G/L:
$14.725 Last:
188,705 Volume:
$14.98 Open:
